Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00697073 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients
A Phase 3 study, sponsored by Santhera Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 68
- Enrollment target
NCT00697073 is a Phase 3 study that has completed, run by Santhera Pharmaceuticals. The registered enrollment target is 68 participants.
The verdict
NCT00697073, a Phase 3 study, has completed, sponsored by Santhera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 68 participants
- Enrollment target
Study Summary
This study is meant to assess the safety and tolerability of idebenone in patients with Friedreich's Ataxia over a 12 months period.
Interventions
- DRUG Idebenone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2008-07 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00697073
The ClinicalTrials.gov registry entry for NCT00697073 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Santhera Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Idebenone is the first listed.
NCT00697073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00697073 about?
NCT00697073 is a clinical study titled "Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients". This study is meant to assess the safety and tolerability of idebenone in patients with Friedreich's Ataxia over a 12 months period.
What is the current status of trial NCT00697073?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 68 participants. The study started on 2008-07. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00697073?
The interventions under investigation include: Idebenone (DRUG).
Who is sponsoring clinical trial NCT00697073?
This trial is sponsored by Santhera Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.